Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/23066
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKalambokis, G.en
dc.contributor.authorManousou, P.en
dc.contributor.authorSamonakis, D.en
dc.contributor.authorGrillo, F.en
dc.contributor.authorDhillon, A. P.en
dc.contributor.authorPatch, D.en
dc.contributor.authorO'Beirne, J.en
dc.contributor.authorRolles, K.en
dc.contributor.authorBurroughs, A. K.en
dc.date.accessioned2015-11-24T19:30:18Z-
dc.date.available2015-11-24T19:30:18Z-
dc.identifier.issn0934-0874-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23066-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectFemaleen
dc.subjectGraft Survivalen
dc.subjectHepatic Veins/physiopathologyen
dc.subjectHepatitis C/*complicationsen
dc.subjectHumansen
dc.subjectLiver Cirrhosis/physiopathology/surgery/*virologyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPrognosisen
dc.subjectRecurrenceen
dc.subjectTreatment Outcomeen
dc.subjectVenous Pressure/physiologyen
dc.titleClinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradienten
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1111/j.1432-2277.2008.00744.x-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/18786149-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1111/j.1432-2277.2008.00744.x/asset/j.1432-2277.2008.00744.x.pdf?v=1&t=h0ulsj3u&s=ab688bbeb5f30fd6182b33e2b2c5c06f4f472903-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2009-
heal.abstractHepatitis C virus (HCV) allograft cirrhosis may progress rapidly requiring re-transplantation but its course is little studied. We evaluated serially biopsied patients who developed HCV-related allograft cirrhosis. We assessed outcome of graft cirrhosis in 55 out of 234 consecutive patients and predictors of decompensation and mortality, including hepatic venous pressure gradient (HVPG) in 38. Allograft cirrhosis (Ishak stage 6, 60%; stage 5, 40%) was diagnosed between 12 and 172 months (median, 52) from transplantation; subsequent follow up was 22 (1-78) months. Faster development (<or=48 months) was associated with tacrolimus and nonuse of azathioprine and prednisolone. Decompensation occurred in 22% with a probability of not developing decompensation reaching 60% at 5 years. Survival among compensated patients was 77% at 5 years, but fell rapidly after decompensation (12% at 1 year). Decompensation and mortality were independently associated with HVPG >or= 10 mmHg, Child-Pugh score >or= 7, and albumin levels <or= 32 g/dl but not with fibrosis stage 5 or 6, HCV genotype (1b, 34%) or immunosuppression used after diagnosis of cirrhosis. In conclusion, Ishak stage 5 and 6 HCV-related cirrhosis have similar prognosis after liver transplantation. An HVPG >or= 10 mmHg, in addition to liver dysfunction, gives independent prognostic information prior to decompensation, allowing early relisting before prognosis becomes extremely poor.en
heal.journalNameTranspl Inten
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Kalambokis-2009-Clinical outcome of.pdf241.67 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons